Discriminative stimulus properties of a new anxiolytic, DN-2327, in rats-Reference-Cited by-同舟云学术

Discriminative stimulus properties of a new anxiolytic, DN-2327, in rats

Published:1993-02 Issue:3 Volume:110 Page:280-286
ISSN:0033-3158
Container-title:Psychopharmacology
language:en
Short-container-title:Psychopharmacology

Author:

Wada Takeo,Fukuda Naohisa

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/BF02251282.pdf

Reference51 articles.

1. Andrews JS, Stephens DN (1990) Drug discrimination models in anxiety and depression. Pharmacol Ther 47:267–280

2. Andrews JS, Stephens DN (1991) Discriminative stimulus properties of the benzodiazepine receptor partial agonistβ-carbolines abecarnil and ZK95962: a comparison with chlordiazepoxide. Behav Pharmacol 2:171–185

3. Ator NA, Griffiths RR (1983) Lorazepam and pentobarbital drug discrimination in baboons: cross-drug generalization and interaction with Ro15-1788. J Pharmacol Exp Ther 226:776–782

4. Ator NA, Griffiths RR (1986) Discriminative stimulus effects of atypical anxiolytics in baboons and rats. J Pharmacol Exp Ther 237:393–403

5. Ator NA, Cook JM, Griffiths RR (1989) Drug discrimination in pentylenetetrazol-trained baboons: generalization to buspirone andβ-carboline-3-carboxylic acid ethyl ester but not lorazepam or pentobarbital. Drug Dev Res 16:257–267

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of buspirone for attenuating cocaine and methamphetamine reinstatement in rats;Drug and Alcohol Dependence;2013-05

2. Placebo Analgesia in Rodents;Placebo and Pain;2013

3. Antianxiety Agents;Burger's Medicinal Chemistry and Drug Discovery;2003-01-15

4. The discriminative stimulus effects of pentylenetetrazol as a model of anxiety: recent developments;Neuroscience & Biobehavioral Reviews;2002-06

5. Differentiating benzodiazepine- and barbiturate-like discriminative stimulus effects of lorazepam, diazepam, pentobarbital, imidazenil and zaleplon in two- versus three-lever procedures;Behavioural Pharmacology;2000-02